Martingale Asset Management L P Has $2,328,000 Holdings in Heska Corporation (HSKA)
Martingale Asset Management L P maintained its stake in Heska Corporation (NASDAQ:HSKA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,802 shares of the medical research company’s stock at the close of the second quarter. Martingale Asset Management L P owned about 0.32% of Heska Corporation worth $2,328,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Victory Capital Management Inc. purchased a new position in shares of Heska Corporation in the 1st quarter valued at $101,000. BNP Paribas Arbitrage SA increased its holdings in shares of Heska Corporation by 1,306.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,167 shares of the medical research company’s stock valued at $123,000 after acquiring an additional 1,084 shares during the period. State of Alaska Department of Revenue purchased a new position in shares of Heska Corporation in the 2nd quarter valued at $127,000. LS Investment Advisors LLC increased its holdings in shares of Heska Corporation by 411.2% in the 2nd quarter. LS Investment Advisors LLC now owns 1,278 shares of the medical research company’s stock valued at $130,000 after acquiring an additional 1,028 shares during the period. Finally, Mason Street Advisors LLC purchased a new position in shares of Heska Corporation in the 1st quarter valued at $144,000. Institutional investors and hedge funds own 81.36% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.dailypolitical.com/2017/09/19/martingale-asset-management-l-p-has-2328000-holdings-in-heska-corporation-hska.html.
Heska Corporation (HSKA) opened at 93.99 on Tuesday. The stock has a 50 day moving average price of $98.69 and a 200-day moving average price of $98.84. Heska Corporation has a one year low of $46.51 and a one year high of $115.00. The stock has a market capitalization of $679.17 million, a P/E ratio of 47.91 and a beta of 0.91.
Heska Corporation (NASDAQ:HSKA) last posted its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Heska Corporation had a return on equity of 15.87% and a net margin of 10.70%. The business had revenue of $34.30 million for the quarter, compared to analyst estimates of $33.35 million. During the same quarter in the prior year, the company earned $0.35 earnings per share. The company’s revenue was up 14.3% on a year-over-year basis. Analysts anticipate that Heska Corporation will post $2.04 earnings per share for the current year.
In other news, CFO John Mcmahon sold 2,608 shares of the company’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $101.17, for a total transaction of $263,851.36. Following the sale, the chief financial officer now owns 193 shares of the company’s stock, valued at $19,525.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Nancy Wisnewski sold 825 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $102.21, for a total value of $84,323.25. Following the sale, the executive vice president now directly owns 38,114 shares in the company, valued at approximately $3,895,631.94. The disclosure for this sale can be found here. 14.70% of the stock is currently owned by corporate insiders.
A number of research analysts have recently issued reports on the company. B. Riley reiterated a “neutral” rating and issued a $96.50 price target on shares of Heska Corporation in a report on Thursday, August 3rd. BidaskClub upgraded Heska Corporation from a “hold” rating to a “buy” rating in a report on Thursday, August 3rd. Benchmark Co. reiterated a “buy” rating and issued a $120.00 price target (up from $106.00) on shares of Heska Corporation in a report on Wednesday, August 9th. Aegis lifted their price target on Heska Corporation from $114.50 to $129.50 and gave the company a “buy” rating in a report on Tuesday, August 1st. Finally, Zacks Investment Research upgraded Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 price target on the stock in a report on Friday, August 4th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $105.20.
About Heska Corporation
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corporation (NASDAQ:HSKA).
Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.